 The down-modulation of the ?-catenin antagonist Chibby 1 (CBY1) associated with the BCR-ABL1 fusion gene of chronic myeloid leukemia (CML) contributes to the aberrant activation of ?-catenin, particularly in leukemic stem cells (LSC) resistant to tyrosine kinase (TK) inhibitors. 